Daiichi Sankyo receives approval for ENHERTU in Japan
ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. The approval of
ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.
A tumour infiltrating lymphocyte (TIL) therapy, lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced on or after prior anti-PD-1/L1 therapy and targeted therapy.
Earlier, ARO-APOC3 received Orphan Drug designation from the FDA and the European Union. ARO-APOC3 is the firm’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It is being developed